ASND vs. BNTX: A Head-to-Head Stock Comparison

Updated on July 7, 2025

Here’s a clear look at ASND and BNTX, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Overview

BNTX’s market capitalization of 26.44 billion USD is significantly greater than ASND’s 10.52 billion USD, highlighting its more substantial market valuation.

BNTX carries a higher beta at 1.28, indicating it’s more sensitive to market moves, while ASND (beta: 0.36) exhibits greater stability.

ASND and BNTX are both American Depositary Receipts (ADRs). This provides U.S. investors with straightforward access to investing in these foreign-listed companies without directly engaging with overseas stock exchanges.

Symbol	ASND	BNTX
Company Name	Ascendis Pharma A/S	BioNTech SE
Country	DK	DE
Sector	Healthcare	Healthcare
Industry	Biotechnology	Biotechnology
CEO	Jan Moller Mikkelsen	Ugur Sahin
Price	174.18 USD	110 USD
Market Cap	10.52 billion USD	26.44 billion USD
Beta	0.36	1.28
Exchange	NASDAQ	NASDAQ
IPO Date	January 28, 2015	October 10, 2019
ADR	Yes	Yes

Historical Performance

This chart compares the performance of ASND and BNTX by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.

Data is adjusted for dividends and splits.

ASND vs. BNTX: Growth of a $10,000 investment over the past one year.

Profitability

Return on Equity

ASND

191.42%

Biotechnology Industry

Max: 72.39%
Q3: -6.30%
Median: -32.82%
Q1: -68.26%
Min: -147.61%

ASND’s Return on Equity of 191.42% is exceptionally high, placing it well beyond the typical range for the Biotechnology industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

BNTX

-4.04%

Biotechnology Industry

Max: 72.39%
Q3: -6.30%
Median: -32.82%
Q1: -68.26%
Min: -147.61%

BNTX has a negative Return on Equity of -4.04%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

ASND vs. BNTX: A comparison of their ROE against the Biotechnology industry benchmark.

Return on Invested Capital

ASND

-50.64%

Biotechnology Industry

Max: 48.74%
Q3: -10.68%
Median: -31.65%
Q1: -52.92%
Min: -113.69%

ASND has a negative Return on Invested Capital of -50.64%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.

BNTX

-5.30%

Biotechnology Industry

Max: 48.74%
Q3: -10.68%
Median: -31.65%
Q1: -52.92%
Min: -113.69%

BNTX has a negative Return on Invested Capital of -5.30%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.

ASND vs. BNTX: A comparison of their ROIC against the Biotechnology industry benchmark.

Net Profit Margin

ASND

-92.67%

Biotechnology Industry

Max: 87.75%
Q3: -5.05%
Median: -103.44%
Q1: -1,032.77%
Min: -2,366.07%

ASND has a negative Net Profit Margin of -92.67%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

BNTX

-28.30%

Biotechnology Industry

Max: 87.75%
Q3: -5.05%
Median: -103.44%
Q1: -1,032.77%
Min: -2,366.07%

BNTX has a negative Net Profit Margin of -28.30%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

ASND vs. BNTX: A comparison of their Net Profit Margin against the Biotechnology industry benchmark.

Operating Profit Margin

ASND

-90.54%

Biotechnology Industry

Max: 87.75%
Q3: -3.28%
Median: -115.26%
Q1: -1,188.86%
Min: -2,943.30%

ASND has a negative Operating Profit Margin of -90.54%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

BNTX

-39.48%

Biotechnology Industry

Max: 87.75%
Q3: -3.28%
Median: -115.26%
Q1: -1,188.86%
Min: -2,943.30%

BNTX has a negative Operating Profit Margin of -39.48%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

ASND vs. BNTX: A comparison of their Operating Margin against the Biotechnology industry benchmark.

Profitability at a Glance

Symbol	ASND	BNTX
Return on Equity (TTM)	191.42%	-4.04%
Return on Assets (TTM)	-32.19%	-3.65%
Return on Invested Capital (TTM)	-50.64%	-5.30%
Net Profit Margin (TTM)	-92.67%	-28.30%
Operating Profit Margin (TTM)	-90.54%	-39.48%
Gross Profit Margin (TTM)	85.30%	79.35%

Financial Strength

Current Ratio

ASND

1.04

Biotechnology Industry

Max: 28.73
Q3: 13.97
Median: 6.31
Q1: 3.60
Min: 0.02

ASND’s Current Ratio of 1.04 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

BNTX

10.18

Biotechnology Industry

Max: 28.73
Q3: 13.97
Median: 6.31
Q1: 3.60
Min: 0.02

BNTX’s Current Ratio of 10.18 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

ASND vs. BNTX: A comparison of their Current Ratio against the Biotechnology industry benchmark.

Debt-to-Equity Ratio

ASND

-4.46

Biotechnology Industry

Max: 0.46
Q3: 0.22
Median: 0.06
Q1: 0.02
Min: 0.00

ASND has a Debt-to-Equity Ratio of -4.46, which indicates negative shareholder equity where liabilities exceed assets. This is a critical sign of financial distress.

BNTX

0.02

Biotechnology Industry

Max: 0.46
Q3: 0.22
Median: 0.06
Q1: 0.02
Min: 0.00

Falling into the lower quartile for the Biotechnology industry, BNTX’s Debt-to-Equity Ratio of 0.02 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.

ASND vs. BNTX: A comparison of their D/E Ratio against the Biotechnology industry benchmark.

Interest Coverage Ratio

ASND

-3.72

Biotechnology Industry

Max: 108.32
Q3: -0.55
Median: -8.49
Q1: -74.83
Min: -168.36

ASND has a negative Interest Coverage Ratio of -3.72. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

BNTX

-21.91

Biotechnology Industry

Max: 108.32
Q3: -0.55
Median: -8.49
Q1: -74.83
Min: -168.36

BNTX has a negative Interest Coverage Ratio of -21.91. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

ASND vs. BNTX: A comparison of their Interest Coverage against the Biotechnology industry benchmark.

Financial Strength at a Glance

Symbol	ASND	BNTX
Current Ratio (TTM)	1.04	10.18
Quick Ratio (TTM)	0.71	10.02
Debt-to-Equity Ratio (TTM)	-4.46	0.02
Debt-to-Asset Ratio (TTM)	0.80	0.01
Net Debt-to-EBITDA Ratio (TTM)	-1.34	23.05
Interest Coverage Ratio (TTM)	-3.72	-21.91

Growth

The following charts compare key year-over-year (YoY) growth metrics for ASND and BNTX. These metrics are based on the companies’ annual financial reports.

Revenue Growth

ASND vs. BNTX: A comparison of their annual year-over-year Revenue Growth.

Earnings Per Share (EPS) Growth

ASND vs. BNTX: A comparison of their annual year-over-year Earnings Per Share (EPS) Growth.

Free Cash Flow Growth

ASND vs. BNTX: A comparison of their annual year-over-year Free Cash Flow Growth.

Dividend

Dividend Yield

ASND

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ASND currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

BNTX

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BNTX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

ASND vs. BNTX: A comparison of their Dividend Yield against the Biotechnology industry benchmark.

Dividend Payout Ratio

ASND

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ASND has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

BNTX

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BNTX has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

ASND vs. BNTX: A comparison of their Payout Ratio against the Biotechnology industry benchmark.

Dividend at a Glance

Symbol	ASND	BNTX
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

Price-to-Earnings Ratio

ASND

-25.98

Biotechnology Industry

Max: 78.44
Q3: 48.98
Median: 20.50
Q1: 12.64
Min: 2.14

ASND has a negative P/E Ratio of -25.98. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.

BNTX

-29.32

Biotechnology Industry

Max: 78.44
Q3: 48.98
Median: 20.50
Q1: 12.64
Min: 2.14

BNTX has a negative P/E Ratio of -29.32. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.

ASND vs. BNTX: A comparison of their P/E Ratio against the Biotechnology industry benchmark.

Forward P/E to Growth Ratio

ASND

-2.36

Biotechnology Industry

Max: 2.29
Q3: 1.10
Median: 0.49
Q1: 0.16
Min: 0.02

ASND has a negative Forward PEG Ratio of -2.36. This typically results from negative earnings or forecasts of declining future earnings, making the ratio not meaningful for valuation.

BNTX

1.09

Biotechnology Industry

Max: 2.29
Q3: 1.10
Median: 0.49
Q1: 0.16
Min: 0.02

BNTX’s Forward PEG Ratio of 1.09 is within the middle range of its peers in the Biotechnology industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.

ASND vs. BNTX: A comparison of their Forward PEG Ratio against the Biotechnology industry benchmark.

Price-to-Sales Ratio

ASND

24.22

Biotechnology Industry

Max: 110.90
Q3: 59.76
Median: 11.33
Q1: 4.45
Min: 0.17

ASND’s P/S Ratio of 24.22 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

BNTX

8.30

Biotechnology Industry

Max: 110.90
Q3: 59.76
Median: 11.33
Q1: 4.45
Min: 0.17

BNTX’s P/S Ratio of 8.30 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

ASND vs. BNTX: A comparison of their P/S Ratio against the Biotechnology industry benchmark.

Price-to-Book Ratio

ASND

-46.77

Biotechnology Industry

Max: 15.78
Q3: 7.44
Median: 3.31
Q1: 1.58
Min: 0.31

The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.

BNTX

1.20

Biotechnology Industry

Max: 15.78
Q3: 7.44
Median: 3.31
Q1: 1.58
Min: 0.31

The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.

ASND vs. BNTX: A comparison of their P/B Ratio against the Biotechnology industry benchmark.

Valuation at a Glance

Symbol	ASND	BNTX
Price-to-Earnings Ratio (P/E, TTM)	-25.98	-29.32
Forward PEG Ratio (TTM)	-2.36	1.09
Price-to-Sales Ratio (P/S, TTM)	24.22	8.30
Price-to-Book Ratio (P/B, TTM)	-46.77	1.20
Price-to-Free Cash Flow Ratio (P/FCF, TTM)	-29.03	-19.67
EV-to-EBITDA (TTM)	-37.74	-29.74
EV-to-Sales (TTM)	25.11	4.68